流式细胞术检测甲状腺癌患者外周血T细胞亚群及其与临床病理的关系

The regulatory T cells in peripheral blood and clinicopathological features in patients with thyroid carcinoma

目的 探讨应用流式细胞术检测甲状腺癌患者细胞免疫功能的方法及其与临床病理的关系.方法 应用三色免疫荧光流式细胞仪测定25例甲状腺癌患者及10例甲状腺良性肿瘤对照者外周血T细胞亚群CD4＋CD25＋Treg/CD4＋Treg比值.结果 甲状腺癌患者外周血中CD4＋CD25＋/CD4＋（%）为72.62±3.16,良性肿瘤对照组为43.36±3.04,差异有统计学意义（P＜0.01）,甲状腺癌患者外周血中CD4＋CD25＋/CD8＋为0.70±0.08,良性肿瘤对照组为0.43±0.05,甲状腺癌中的升高更明显（P＜0.05）.甲状腺癌外周血中的CD4＋CD25＋Treg细胞所占比值与甲状腺癌患者的年龄、性别、肿瘤的位置、大小、病理类型、临床分期无明显相关（P＞0.05）.结论 甲状腺癌患者外周血中CD4＋CD25＋Treg增多.CD4＋CD25＋Treg与CD4＋T细胞的比例亦升高.甲状腺癌患者外周血中CD4＋CD25＋Treg在甲状腺癌的早期即已经升高.

Objective To analyze the component of T cells in the microenviroment around thyroid carcinoma, especially CD4＋ CD25＋ regulatory T cells, and observe the relationship between CD4＋ CD25＋ regulatory T cells and the clinicopathological characters. Methods The enrolled included 25 patients with thyroid carcinoma and 10 patients with benign diseases of thyroid having different clinical symptoms. We got from peripheral blood,send to the laboratory immediately and digested by the mixed enzymes to single cells, separated by density gradient centrifugation, flow cytometry to check CD4, CD8 and CD25 expressed on the surface of the cell, then analyze the component of the subpopulation of T cell, especially the cell co-expressed CD4 and CD25 molecular. Collect the clinical and pathologic characters of cancer patient, use statistic software to analyze the relationship between CD4＋ CD25＋ regulatory T cell and the clinic pathologic characters. Results It is higher that the CD4＋ CD25＋ regulatory T cell subset in T lymphocyte in the thyroid carcinoma than that of benign diseases （P 〈 0.01）, （73.62±3.16） % vs （43.36 ±3.04） % , while CD4＋ CD25＋ Treg/CD8＋ T is higher in thyroid cancer than that in benign disease （ P 〈 0.05） , 0.70 ± 0.08 vs 0.43 ±0.05.Analyze the relationship between CD4＋ CD25＋Treg and the clinic pathologic characters with SPSS, result shows that there are no significant relationship between them （ P 〉 0.05）. Conclusion CD4＋ CD25＋ regulatory T cell is prevalent in thyroid carcinoma. The prevalence of CD4＋ CD25＋ regulatory T cell around cancer cells may be happened in the early stage.